Journal of Commercial Biotechnology New Issue Published
The latest issue of the Journal of Commercial Biotechnology is now available. Check out the Table of Contents below, and […]
Journal of Commercial Biotechnology New Issue Published Read Post »
The latest issue of the Journal of Commercial Biotechnology is now available. Check out the Table of Contents below, and […]
Journal of Commercial Biotechnology New Issue Published Read Post »
This is a guest post from Brannon Cashion, President of Addison Whitney Health. Do you have a response to Brannin’s post?
Branding Biotech – Communicating the Brand’s Point of Differentiation Read Post »
Following two posts on Brexit and British biotechnology, I would like to provide a perspective that turns everything on its
In the wake of my recent post on the potential impact of Brexit on British Biotechnology, I am fortunate to
Brexit and British Biotech; A Second Look from ESOF Read Post »
I have a tool that can be used to measure the impact of Brexit on biotechnology in the United Kingdom.
DrugPatentWatch offers PDF copies of the FDA Orange Book dating back to 1980. The Food and Administration (FDA) Orange Book, or Approved
On Thursday June 9th from 10:30 to 11:30pm in Room 124 North Mike May and I will be going over the
Get your Worldview on — Measuring Global Biotechnology at #BIO2016 Read Post »
My book signing sold out, but do not despair — you can still get a signed copy. Signed copies of Building
I will be signing my textbook Building Biotechnology, and other books, in the BIO bookstore on Wednesday June 8th from 12:30 pm
This is a guest post from Robert Yapundich, MD and Gregory Schimizzi, MD. Dr. Yapundich is a practicing neurologist in Hickory, North Carolina and a
Biosimilar Naming: Distinguishable or Disingenuous? Read Post »